NeuroOne Q1 FY2023 net loss $1.7M; FDA cleared Evo sEEG electrode

NEUROONE MEDICAL TECHNOLOGIES Corp

2023-Q1 EPS reported -$0.11 revenue$114,579

Product revenue $115K (vs $34K YoY); collaboration revenue $1.46M from Zimmer agreement.
Net loss $1.7M (improved from $2.8M); cash $7.6M, no debt as of Dec 31, 2022.
FDA 510(k) clearance for Evo sEEG electrode; first commercial order shipped to Zimmer Biomet.
Targeting OneRF ablation system 510(k) submission in Q2 calendar 2023; spinal cord stimulation electrodes in pre-clinical.
R&D expense $1.6M (up from $1.1M); SG&A flat at $1.7M; total op ex $3.2M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

NEUROONE MEDICAL TECHNOLOGIES Corp reported financial results for the fiscal first quarter 2023 ended December 31, 2022.

Period: the fiscal first quarter 2023 ended December 31, 2022
Result: reported results

Exact text from the filing

On February 14, 2023, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

NEUROONE MEDICAL TECHNOLOGIES Corp filing history →

Source: SEC EDGAR

accession 0001213900-23-011512

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.